Navigation Links
Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascent's Neurogenesis Platform
Date:11/4/2009

CLARKSVILLE, Md., Nov. 4 /PRNewswire/ -- Neuronascent, Inc., a privately-held biotechnology company developing novel, neurogenic small-molecule drugs for the treatment of depression, Alzheimer's disease, Parkinson's and other neurodegenerative diseases, announces it has entered into a discovery agreement with ChemRar Pharma, a Russian biotechnology start-up company focusing on small-molecule modulators for developmental pathways and stem cells to treat cancer. Under the terms of the agreement, Neuronascent will screen certain ChemRar proprietary developmental pathway inhibitors utilizing their proprietary drug discovery platform for neurogenesis and neuroprotection. Financial terms of the collaboration were not disclosed.

The agreement matches ChemRar's discovery and translational research focus through scientific collaboration with Neuronascent's success in discovering novel, neurogenic and neuroprotective drug candidates. The companies intend to evaluate co-development opportunities for future commercialization and funding.

"We are proud to start this collaboration with ChemRar Pharma on these studies, highlighting our expertise in the field of neurogenesis, and look forward to the potential of this relationship," notes Dr. Judith Kelleher-Andersson, President and CSO, Neuronascent, Inc.

Nikolay Merkin, CBO of ChemRar Pharma, comments: "We are pleased that Neuronascent will bring high value to our R&D program and expand the scope of our molecules with their unique and well-established stem cell and neurogenesis platform. We look forward to achieving success in this collaboration."

About ChemRar Pharma:

ChemRar Pharma was established in 2007 in Moscow, Russia under the roof of the ChemRar High Tech Center as an innovative oncology start-up. In 2009, ChemRar in-licensed the portfolio of developmental pathway inhibitors from AllaChem and ChemDiv, Inc. (San Diego, CA) and established the R&D collaboration with ChemDiv's Chemical Diversity Research Institute in Moscow to continue preclinical and clinical development for multiple cancer indications.

About Neuronascent, Inc.:

Founded in 2004 by Dr. Judith Kelleher-Andersson, Neuronascent, Inc. discovers and develops first-in-class, small-molecule therapeutics, based on the science of neurogenesis, that target depression, neurodegenerative diseases, including Alzheimer's and Parkinson's, and Down syndrome. The Company is headquartered in Clarksville, MD and has facilities in Rockville and Walkersville, MD. For additional information, please visit www.neuronascent.com.

Safe Harbor Statement

This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects" and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ moderately from current expectations.

SOURCE Neuronascent, Inc.


'/>"/>
SOURCE Neuronascent, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs
2. BD Announces Results for Fourth Fiscal Quarter and Full Year
3. WebMD Health Corp. Announces Intention To Commence Tender Offer To Repurchase Up To 5,700,000 Shares of its Common Stock
4. Mettler-Toledo International Inc. Announces Webcast of Presentation at Baird Industrial Conference
5. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
6. West Announces Third Quarter 2009 Results
7. Rigel Announces Third Quarter 2009 Financial Results
8. VIVUS Announces Promotion of Peter Tam to President
9. ATS Medical Announces Third Quarter 2009 Results
10. BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology
11. PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Research and Markets has announced the addition of the ... (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type of Lab (Hospital, ... HIV/AIDS etc.), Forecast to 2022" report to their offering. ... US ... clinical lab testing, which has evolved as a major source ...
(Date:1/21/2017)... , Jan. 20, 2017  Today, ... Symposia Conference, "PI3K Pathways in Immunology, Growth ... (NASDAQ: INFI ) presented ... development candidate that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). ... to help overcome resistance to checkpoint inhibition ...
(Date:1/20/2017)... 2017 Research and Markets has announced ... Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company ... ... Hearing Aids Market Sales Volume, Company Analysis and Forecast to ... aid industry. The growing prevalence of hearing impairment ...
Breaking Medicine Technology:
(Date:1/23/2017)... California (PRWEB) , ... January 23, 2017 , ... Old ... principles, has added Mr. Olympia Classic Physique bodybuilder Breon Ansley to its growing team ... competing as a bodybuilder in 2012 and in less than a year was able ...
(Date:1/23/2017)... ... , ... “The Inn at the Mill”: a story of love and redemption, hope and ... happy and content. , “The Inn at the Mill” is the creation of published ... Vermont and is now living in Berks County on Crow Hill. The inn, ...
(Date:1/23/2017)... , ... January 23, 2017 , ... “Life Under Blankets”: ... depression from an early age. “Life Under Blankets” is the creation of published author, ... Illinois, Circle Campus in Chicago. She went on to pursue a master’s degree in ...
(Date:1/22/2017)... ... ... Phytocéane invites clients to take an exotic journey deep into the heart ... CREAM. Inspired by the beauty of Zanzibar, a Tanzanian archipelago off the coast of ... to create this gentle, velvety body cream to envelop the skin in moisture while ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals and ... a simple test will take days to arrive to the end customer, having to ... access to their lab tests, bypassing the cost and delay of traditional means. Now ...
Breaking Medicine News(10 mins):